Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ICOS Corporation (NasdaqNM:ICOS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
22021 - 20th Avenue S.E.
Bothell, WA 98021
Phone: (425) 485-1900
Fax: (425) 485-1911
Email: info@icos.com
Employees (last reported count): 386
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 20%
·Over the last 6 months:
 · one insider buy; 0  shares
 · 3 insider sells; 54.0K shares
  (0.5% of insider shares)
·Institutional: 49% (61% of float)
(221 institutions)
·Net Inst. Buying: 3.74M shares (+12.53%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high-throughput drug screening, medicinal chemistry and genomics to develop products with commercial potential. The Company is evaluating Cialis, a small molecule compound that inhibits the phosphodiesterase type five enzyme for the treatment of male erectile dysfunction and female sexual dysfunction. The Company is also evaluating Pafase, a recombinant human serum protein, for the treatment of sepsis and other diseases characterized by increased activity of platelet-activating factor.
More from Market Guide: Expanded Business Description

Financial Summary
ICOS is discovering and developing new pharmaceuticals by seeking points of intervention in disease processes that may lead to more specific and efficacious drugs. For the six months ended 6/30/01, revenues rose 44% to $52.9 million. Net loss before accounting change rose 61% to $20.4 million. Revenues reflect the inclusion of a $15 million license fee from Lilly ICOS. Net loss reflects an increase in equity in losses of affiliates.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Paul Clark, 54
Chairman, Pres, CEO
$878K--  
Michael Stein, 51
CFO, VP
--  --  
Gary Wilcox, Ph.D., 54
Exec. VP of Operations, Sec.
416K$112K
Leonard Blum, 40
VP of Sales and Marketing
--  --  
W. Gallatin, Ph.D., 47
VP and Scientific Director
308K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ICOSAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$36.438
Recent Price$58.30 
52-Week High
on 5-June-2001
$70.10 
Beta0.76 
Daily Volume (3-month avg)551.8K
Daily Volume (10-day avg)508.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-2.1%
52-Week Change
relative to S&P500
+31.3%
Share-Related Items
Market Capitalization$3.13B
Shares Outstanding53.6M
Float42.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.85 
Earnings (ttm)-$0.86 
Earnings (mrq)-$0.10 
Sales (ttm)$2.14 
Cash (mrq)$3.81 
Valuation Ratios
Price/Book (mrq)15.12 
Price/EarningsN/A 
Price/Sales (ttm)27.28 
Income Statements
Sales (ttm)$106.8M
EBITDA (ttm)-$30.1M
Income available to common (ttm)-$42.5M
Profitability
Profit Margin (ttm)-39.8%
Operating Margin (ttm)6.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-22.00%
Return on Equity (ttm)-27.36%
Financial Strength
Current Ratio (mrq)6.30 
Debt/Equity (mrq)0 
Total Cash (mrq)$204.3M
Short Interest
As of 8-Aug-2001
Shares Short1.91M
Percent of Float4.4%
Shares Short
(Prior Month)
2.01M
Short Ratio4.95 
Daily Volume385.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.